$0.13

+0.02 (+17.45%)

Weekly Expected Move ±23.1%

$0 $0 $0 $0 $0

NYSE · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 46 · $263.9M mcap · 2.04B float · 0.0008% daily turnover

Revenue

$48.2B -0.2% ▼

5Y CAGR: +2.5%

Gross Profit

$34.9B +27.4% ▲

5Y CAGR: +2.6%

Operating Income

$15.1B +56.5% ▲

5Y CAGR: +47.3%

Net Income

$7.1B +178.8% ▲

EPS (Diluted)

$3.46 +178.5% ▲

EBITDA

$19.2B +507.3% ▲

5Y CAGR: +31.3%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$46.4B	$46.2B	$45.0B	$48.3B	$48.2B
YoY Growth	+9.1%	-0.5%	-2.5%	+7.3%	-0.2%
Cost of Revenue	$9.9B	$10.1B	$10.7B	$20.9B	$13.2B
Gross Profit	$36.4B	$36.0B	$34.3B	$27.4B	$34.9B
Gross Margin	78.6%	78.0%	76.2%	56.8%	72.5%
R&D Expenses	$10.2B	$9.5B	$9.3B	$11.2B	$10.0B
SG&A Expenses	$7.7B	$7.8B	$7.8B	$7.9B	$7.3B
Operating Expenses	$27.9B	$26.9B	$26.1B	$17.8B	$20.0B
Operating Income	$8.5B	$9.1B	$8.2B	$9.7B	$15.1B
Operating Margin	18.4%	19.7%	18.2%	20.0%	31.4%
Interest Expense	$1.3B	$1.2B	$1.2B	$1.9B	$1.9B
Income Before Tax	$8.1B	$7.7B	$8.4B	-$8.4B	$9.3B
Tax Expense	$1.1B	$1.4B	$400M	$554M	$2.3B
Net Income	$7.0B	$6.3B	$8.0B	-$8.9B	$7.1B
Net Margin	15.1%	13.7%	17.8%	-18.5%	14.6%
EPS (Diluted)	$3.12	$2.95	$3.86	$-4.41	$3.46
EBITDA	$20.1B	$19.2B	$19.4B	$3.2B	$19.2B
Shares Outstanding	2.25B	2.15B	2.08B	2.03B	2.04B

Line Item	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1
Revenue	$12.2B	$11.9B	$12.3B	$11.2B	$12.3B	$12.2B	$12.5B	$11.5B
Cost of Revenue	$3.3B	$5.3B	$4.9B	$3.9B	$4.2B	$4.2B	$4.2B	$3.4B
Gross Profit	$8.9B	$6.6B	$7.4B	$7.3B	$8.1B	$8.1B	$8.3B	$8.1B
Gross Margin	73.2%	55.6%	60.2%	65.5%	65.8%	66.0%	66.2%	70.2%
R&D Expenses	$2.9B	$2.4B	$2.8B	$2.3B	$2.6B	$2.5B	$2.6B	$2.2B
SG&A Expenses	$1.9B	$2.0B	$2.1B	$1.6B	$1.7B	$1.8B	$2.1B	$1.6B
Operating Expenses	$7.2B	$4.4B	$4.9B	$3.8B	$4.0B	$4.2B	$4.6B	$4.3B
Operating Income	$1.7B	$2.3B	$2.5B	$3.5B	$4.1B	$3.8B	$3.6B	$3.8B
Operating Margin	13.9%	19.2%	20.5%	31.4%	33.6%	31.5%	29.1%	32.9%
Interest Expense	$521M	$505M	$496M	$494M	$485M	$480M	$432M	$411M
Income Before Tax	$1.3B	$1.7B	$175M	$3.0B	$1.8B	$3.1B	$1.5B	$3.2B
Tax Expense	-$398M	$461M	$99M	$509M	$460M	$919M	$384M	$561M
Net Income	$1.7B	$1.2B	$72M	$2.5B	$1.3B	$2.2B	$1.1B	$2.7B
Net Margin	13.8%	10.2%	0.6%	21.9%	10.7%	18.0%	8.7%	23.3%
EPS (Diluted)	$0.83	$0.60	$0.04	$1.20	$0.64	$1.08	$0.53	$1.31
EBITDA	$4.4B	$4.8B	$2.5B	$4.5B	$3.3B	$4.6B	$4.7B	$3.8B
Shares Outstanding	2.03B	2.03B	2.04B	2.04B	2.04B	2.04B	2.04B	2.05B

CELG-RI NYSE